tiprankstipranks
Denali Therapeutics (DNLI)
:DNLI
US Market

Denali Therapeutics (DNLI) Ownership - Who Owns Denali Therapeutics?

Compare
672 Followers

Denali Therapeutics (DNLI) Ownership Overview

9.11%32.60%30.32%14.96%13.01%
30.32% Other Institutional Investors
14.96% ETFs
13.01% Public Companies and
Individual Investors
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 77.88% of the company’s stock is owned by Institutional Investors, 9.11% is owned by Insiders, and 13.01% is owned by Public Companies and Individual Investors.
The ownership structure of Denali Therapeutics (DNLI) stock is a mix of institutional, retail, and individual investors. Approximately 62.92% of the company’s stock is owned by Institutional Investors, 9.11% is owned by Insiders, and 14.96% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jan 08, 2025
xxxxxxxxxxxxx
$69485
Jan 08, 2025
xxxxxxxxxxxxx
$308291
Jan 08, 2025
Ryan J. Watts
President & Ceo,director
xxxxxxxxxxxxx
$750955
Jan 08, 2025
Alexander O. Schuth
Cofo And Secretary
xxxxxxxxxxxxx
$308291

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$421988
Dec 31, 2024
xxxxxxxxxxxxx
$2038000
Dec 31, 2024
xxxxxxxxxxxxx
$16151129

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
11,347,386Institution7.81%171,912,898
10,210,524Institution7.03%154,689,439
8,797,384Institution6.06%133,280,368
6,115,614Institution4.21%92,651,552
5,750,882Insider4.20%87,125,862
3,807,529Institution2.62%57,684,064
3,795,618Institution2.61%57,503,613
3,731,695Institution2.57%56,535,179
2,455,675Insider1.69%37,203,476
2,117,408Insider1.46%32,078,731

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,210,524Institution7.03%154,689,439
8,797,384Institution6.06%133,280,368
3,807,529Institution2.62%57,684,064
3,795,618Institution2.61%57,503,613
2,041,163Institution1.41%30,923,619
1,702,336Institution1.17%25,790,390
1,578,311Institution1.09%23,911,412
1,386,680Institution0.95%21,008,202
1,251,766Institution0.86%18,964,255
1,031,060Institution0.71%15,620,559

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,736,955Institution2.57%61,883,975
3,368,820Institution2.32%51,037,623
2,931,924Institution2.02%59,752,611
1,893,590Institution1.30%31,357,850
1,661,237Institution1.14%38,706,822
1,476,212Institution1.02%21,980,797
760,946Institution0.52%11,528,332
627,876Institution0.43%9,512,321
578,180Institution0.40%8,609,100
570,068Institution0.39%9,440,326

FAQ

Who Owns Denali Therapeutics (DNLI)?
According to the latest TipRanks data, approximately 30.32% of the company's stock is held by institutional investors, 9.11% is held by insiders, and 13.01% is held by retail investors.
    What percentage of Denali Therapeutics (DNLI) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 30.32% of Denali Therapeutics (DNLI) stock is held by institutional investors.
      What percentage of Denali Therapeutics (DNLI) stock is held by retail investors?
      According to the latest TipRanks data, approximately 13.01% of Denali Therapeutics (DNLI) stock is held by retail investors.
        Who owns the most shares of Denali Therapeutics (DNLI)?
        Vanguard owns the most shares of Denali Therapeutics (DNLI).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis